LIVZON PHARMAC. GRP H YC1 (LP6) — Net Asset Quality Index
LIVZON PHARMAC. GRP H YC1 (LP6) has a Net Asset Quality Index of 64.4% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €24.19 Billion minus total liabilities of €8.61 Billion yields net assets of €15.58 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check LP6 financial resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
LIVZON PHARMAC. GRP H YC1 Net Asset Quality Index Over Time (2021–2025)
This chart shows how LIVZON PHARMAC. GRP H YC1's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of March 2026, the index stands at 64.4%, representing net assets of €15.58 Billion against total assets of €24.19 Billion EUR. See LIVZON PHARMAC. GRP H YC1 (LP6) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for LIVZON PHARMAC. GRP H YC1 (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for LIVZON PHARMAC. GRP H YC1 from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see LIVZON PHARMAC. GRP H YC1 market capitalisation.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 64.8% | €15.55 Billion | €23.99 Billion | €8.44 Billion | ▲ +3.9 pp |
| 2024 | 60.9% | €14.91 Billion | €24.46 Billion | €9.55 Billion | ▲ +2.0 pp |
| 2023 | 59.0% | €14.77 Billion | €25.04 Billion | €10.28 Billion | ▼ -1.1 pp |
| 2022 | 60.1% | €14.94 Billion | €24.87 Billion | €9.93 Billion | ▼ -3.9 pp |
| 2021 | 64.0% | €14.31 Billion | €22.37 Billion | €8.06 Billion | — |